Hormonal
Nutrient-stimulated hormone (NuSH) therapies, including GLP-1 and dual/tri-agonists, produce significant weight loss and cardiometabolic improvements in real-world settings, though response heterogeneity, high discontinuation rates, and post-cessation weight regain remain unresolved challenges.
NuSH therapies (like semaglutide or tirzepatide) are highly effective for significant weight loss and metabolic health in real-world use, but they are not magic bullets. Expect a significant portion of people to not respond well, experience side effects leading to stopping the drug, or regain weight after stopping. Success requires individualized dosing, lifestyle support, and an understanding that obesity management is often a long-term commitment rather than a quick fix.
NuSH-based therapeutics effectively reduce weight and improve cardiometabolic outcomes... significant variability exists in patients’ responses... high rate of treatment cessation... tendency for weight regain following treatment cessation.
Why this rating
The paper is a protocol for an observational cohort; it cites existing clinical trial data (e.g., STEP 1, SURMOUNT) but does not yet present new primary outcome data.
Source
Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
Chuwen Lin et al. · BMJ Open · 2026
DOI 10.1136/bmjopen-2025-115236
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →